Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
100 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Malignant Mesothelioma - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Malignant Mesothelioma - Pipeline Review, H2 2014', provides an overview of the Malignant Mesothelioma's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Malignant Mesothelioma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Malignant Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Malignant Mesothelioma Overview 9 Therapeutics Development 10 Pipeline Products for Malignant Mesothelioma - Overview 10 Pipeline Products for Malignant Mesothelioma - Comparative Analysis 11 Malignant Mesothelioma - Therapeutics under Development by Companies 12 Malignant Mesothelioma - Therapeutics under Investigation by Universities/Institutes 14 Malignant Mesothelioma - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Malignant Mesothelioma - Products under Development by Companies 18 Malignant Mesothelioma - Products under Investigation by Universities/Institutes 19 Malignant Mesothelioma - Companies Involved in Therapeutics Development 20 Kyowa Hakko Kirin Co., Ltd. 20 Eli Lilly and Company 21 Bayer AG 22 Aeolus Pharmaceuticals, Inc. 23 Bionomics Limited 24 Biotecnol, Inc. 25 Deciphera Pharmaceuticals, LLC 26 Eagle Pharmaceuticals Inc. 27 SentoClone International AB 28 Verastem, Inc. 29 Formula Pharmaceuticals, Inc. 30 Malignant Mesothelioma - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Combination Products 32 Assessment by Target 33 Assessment by Mechanism of Action 36 Assessment by Route of Administration 39 Assessment by Molecule Type 41 Drug Profiles 43 BNC-105 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 FPI-01 - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 YS-110 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 BIW-8962 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 ONCOS-102 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Drug For Mesothelioma - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Oshadi D + Oshadi R - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 AEOL-10150 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 anetumab ravtansine - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 LY-3023414 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Cell Therapy for Metastatic Pancreatic Cancer and Mesothelioma - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 VS-4718 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 VS-5584 - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 BERTA - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 Drugs to Modulate Aquaporin Channels for Malignant Mesothelioma - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 Ad5-SGE-REIC/Dkk3 Gene Therapy - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 pemetrexed disodium - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Vaccine For Cancer - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 YP-223 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 YYP-218 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 YP-3 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 DP-3975 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 Tb-535C - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 SentoClone - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 Malignant Mesothelioma - Recent Pipeline Updates 76 Malignant Mesothelioma - Dormant Projects 89 Malignant Mesothelioma - Discontinued Products 90 Malignant Mesothelioma - Product Development Milestones 91 Featured News & Press Releases 91 May 05, 2014: MolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesothelioma 91 Jan 22, 2014: European Commission Grants Orphan Drug Status to Eisai's Amatuximab for the Treatment of Malignant Mesothelioma 92 Dec 23, 2013: Engineered T Cells Show Antitumor Activity in Solid Malignancies 92 Oct 23, 2013: Virttu has Mesothelioma Study poster accepted at prestigious World Conference on Lung Cancer 93 Sep 19, 2013: Verastem Reports on Ongoing Trials at Cancer Advance at Harvard Medical School 94 Jul 24, 2013: Verastem Receives Orphan Drug Designation from the U.S. FDA for Defactinib in Mesothelioma 94 Jun 13, 2013: Verastem Receives Orphan Medicinal Product Designation From European Commission For VS-6063 In Mesothelioma 95 Apr 17, 2013: Polaris Scientific Colleagues Present Data Demonstrating Metabolic Changes Induced By ADI-PEG 20 Are Associated With Anticancer Activity In Bladder Cancer And Mesothelioma Models At AACR Annual Meeting 2013 96 Feb 14, 2013: Verastem Files For Orphan Disease Status For VS-6063 In Mesothelioma 97 Jan 09, 2013: Verastem Enters Biomarker Agreement With LabCorp For Cancer Stem Cell Agent Companion Diagnostic 97 Appendix 99 Methodology 99 Coverage 99 Secondary Research 99 Primary Research 99 Expert Panel Validation 99 Contact Us 100 Disclaimer 100
List of Tables Number of Products under Development for Malignant Mesothelioma, H2 2014 10 Number of Products under Development for Malignant Mesothelioma - Comparative Analysis, H2 2014 11 Number of Products under Development by Companies, H2 2014 13 Number of Products under Investigation by Universities/Institutes, H2 2014 14 Comparative Analysis by Clinical Stage Development, H2 2014 15 Comparative Analysis by Early Stage Development, H2 2014 16 Comparative Analysis by Unknown Stage Development, H2 2014 17 Products under Development by Companies, H2 2014 18 Products under Investigation by Universities/Institutes, H2 2014 19 Malignant Mesothelioma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 20 Malignant Mesothelioma - Pipeline by Eli Lilly and Company, H2 2014 21 Malignant Mesothelioma - Pipeline by Bayer AG, H2 2014 22 Malignant Mesothelioma - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2014 23 Malignant Mesothelioma - Pipeline by Bionomics Limited, H2 2014 24 Malignant Mesothelioma - Pipeline by Biotecnol, Inc., H2 2014 25 Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2014 26 Malignant Mesothelioma - Pipeline by Eagle Pharmaceuticals Inc., H2 2014 27 Malignant Mesothelioma - Pipeline by SentoClone International AB, H2 2014 28 Malignant Mesothelioma - Pipeline by Verastem, Inc., H2 2014 29 Malignant Mesothelioma - Pipeline by Formula Pharmaceuticals, Inc., H2 2014 30 Assessment by Monotherapy Products, H2 2014 31 Assessment by Combination Products, H2 2014 32 Number of Products by Stage and Target, H2 2014 35 Number of Products by Stage and Mechanism of Action, H2 2014 38 Number of Products by Stage and Route of Administration, H2 2014 40 Number of Products by Stage and Molecule Type, H2 2014 42 Malignant Mesothelioma Therapeutics - Recent Pipeline Updates, H2 2014 76 Malignant Mesothelioma - Dormant Projects, H2 2014 89 Malignant Mesothelioma - Discontinued Products, H2 2014 90
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.